Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Tran

Showing results (141-150 of 181) with videos related to

Pageof 19
Sort By:
Journal of Proteome Research|August 6, 2010
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver diseaseJonathan Barr, Mercedes Vázquez-Chantada, Cristina Alonso, et al.
EMBO Molecular Medicine|April 2, 2015
Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1Marion Seillier, Laurent Pouyet, Prudence N'Guessan, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 26, 2014
Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammationMeghana N Patel, William G Bernard, Nikolay B Milev, et al.
Developmental Cell|June 29, 2022
Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLDRomain Donne, Maëva Saroul-Ainama, Pierre Cordier, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Journal of Hepatology|August 10, 2018
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosisNathalie Ganne-Carrié, Cendrine Chaffaut, Valérie Bourcier, et al.
Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.
Pageof 19

Showing results (141-150 of 181) with videos related to

Sort By:
Pageof 19
Journal of Proteome Research|August 6, 2010
Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver diseaseJonathan Barr, Mercedes Vázquez-Chantada, Cristina Alonso, et al.
EMBO Molecular Medicine|April 2, 2015
Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1Marion Seillier, Laurent Pouyet, Prudence N'Guessan, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 26, 2014
Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammationMeghana N Patel, William G Bernard, Nikolay B Milev, et al.
Developmental Cell|June 29, 2022
Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLDRomain Donne, Maëva Saroul-Ainama, Pierre Cordier, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized studyTarik Asselah, Stanislas Pol, Christophe Hezode, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Journal of Hepatology|August 10, 2018
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosisNathalie Ganne-Carrié, Cendrine Chaffaut, Valérie Bourcier, et al.
Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Journal of Hepatology|March 15, 2012
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirinDominique Larrey, Ansgar W Lohse, Victor de Ledinghen, et al.
Pageof 19